Literature DB >> 2187866

Characterization of an insulin receptor mutant lacking the subunit processing site.

J F Williams1, D A McClain, T J Dull, A Ullrich, J M Olefsky.   

Abstract

An insulin receptor mutant was constructed utilizing site-directed mutagenesis to delete the Arg-Lys-Arg-Arg basic amino acid cleavage site (positions 720-723) from the cDNA encoding the human insulin proreceptor. This mutant was transfected into Chinese hamster ovary cells. Immunoprecipitation of metabolically labeled cells revealed a 205-kDa proreceptor which bound to wheat germ agglutinin. Processed 130-kDa alpha and 95-kDa beta subunits were also observed and contained approximately 20% as much protein as the proreceptor on a molar basis. Trypsin digestion of intact metabolically labeled cells decreased the proreceptor band by 80%. Pulse-chase studies revealed a half-life of 28 h for the proreceptor. When cells were photolabeled with 125I-B2(2-nitro-4-azidophenylacetyl)-des-PheB1 (NAPA)-insulin, the proreceptor incorporated 10% as much label as the 130-kDa alpha subunit in spite of a 5-fold molar excess. Incubation of NAPA-labeled cells at 37 degrees C for 20 min resulted in 60% of the labeled subunits, but little labeled proreceptor, becoming resistant to trypsin degradation. Immunoprecipitation of NAPA-insulin-stimulated cells with anti-phosphotyrosine antibodies revealed that 62% of the processed labeled receptors, but very little proreceptor, contained phosphotyrosine. Thus, this mutant receptor is synthesized, glycosylated, and expressed on the cell surface as uncleaved proreceptor, although some processing to alpha and beta subunits still occurs. It exhibits a markedly decreased affinity for insulin, and when insulin is bound to, demonstrates defective internalization, down-regulation, and autophosphorylation. These data suggest that cleavage of the mutant proreceptor into subunits is required not only for the development of high affinity binding sites, but also for normal transduction of the signal which activates the beta subunit tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187866

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations.

Authors:  Feng Qian; Alessandra Boletta; Anil K Bhunia; Hangxue Xu; Lijuan Liu; Ali K Ahrabi; Terry J Watnick; Fang Zhou; Gregory G Germino
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

2.  A Kex2-related endopeptidase activity present in rat liver specifically processes the insulin proreceptor.

Authors:  C Alarcón; B Cheatham; B Lincoln; C R Kahn; K Siddle; C J Rhodes
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

3.  Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.

Authors:  S Rong; M Bodescot; D Blair; J Dunn; T Nakamura; K Mizuno; M Park; A Chan; S Aaronson; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

4.  An extracellular domain of the beta subunit is essential for processing, transport and kinase activity of insulin receptor.

Authors:  T Haruta; T Sawa; Y Takata; T Imamura; Y Takada; H Morioka; G H Yang; M Kobayashi
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

5.  Expression of the receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the CAM-like extracellular region.

Authors:  M Streuli; N X Krueger; P D Ariniello; M Tang; J M Munro; W A Blattler; D A Adler; C M Disteche; H Saito
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

6.  Differential Effects of Furin Deficiency on Insulin Receptor Processing and Glucose Control in Liver and Pancreatic β Cells of Mice.

Authors:  Ilaria Coppola; Bas Brouwers; Sandra Meulemans; Bruno Ramos-Molina; John W M Creemers
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.